Synopsis: Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare, will acquire a 30.4% stake in Spanish biotech company Gate2Brain for €7 million (around Rs. 63 crore). The partnership will focus on developing a promising brain cancer treatment and expanding Shilpa’s presence in innovative oncology therapies.
Shares of Shilpa Medicare Ltd, with a market capitalization of Rs. 10,001.08 crore, are trading at a price of Rs. 511.35, down 1.16% from its previous closing price of Rs. 517.35. The stock touched an intraday high of Rs. 522.85 and a low of Rs. 502.40. It is trading at a P/E ratio of 41.38.
Pharmaceutical company Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, will acquire a 30.4% stake in Barcelona-based biotechnology company Gate2Brain S.L. The investment, valued at €7 million (approximately Rs. 63 crore), was disclosed in a regulatory filing submitted to the stock exchanges on June 3, 2026.
The transaction includes an upfront cash investment of €0.5 million, €1 million earmarked for project development, and €5.5 million in milestone-based equity consideration linked to services provided by Shilpa. The company stated that the deal is being carried out on an arm’s-length basis and does not require any regulatory approvals.
Focus on Advanced Brain Cancer Treatment
Gate2Brain is a biotechnology company specializing in technologies that help medicines cross the blood-brain barrier, a protective layer that often prevents drugs from reaching the brain effectively. As part of the partnership, Shilpa will become Gate2Brain’s manufacturing, regulatory, and development partner for its lead drug candidate, G2B-002.
The therapy is designed to treat aggressive pediatric brain cancers, including Diffuse Intrinsic Pontine Glioma (DIPG)and Pediatric Glioblastoma (pGBM), two diseases with very limited treatment options.
G2B-002 uses Gate2Brain’s proprietary peptide-based delivery technology to transport SN-38, a powerful anti-cancer drug, directly into brain tissue. According to preclinical studies, the platform has shown significantly improved drug delivery compared to conventional approaches.
The drug candidate has already received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), highlighting its potential in addressing rare diseases with unmet medical needs. The partnership aligns with Shilpa Medicare’s strategy of investing in innovative healthcare technologies with long-term growth potential.
By combining Gate2Brain’s scientific expertise with Shilpa’s manufacturing and regulatory capabilities, both companies aim to accelerate the development of G2B-002. Clinical trial material is expected to be manufactured next year, while first-in-human clinical studies are anticipated to begin by FY28.
The opportunity is significant, as demand for advanced brain cancer treatments continues to grow globally. The collaboration could position Shilpa to participate in a high-value segment of the oncology market while strengthening its presence in specialty and innovative therapies.
Management Commentary
Commenting on the partnership, Vishnukant Bhutada, Managing Director of Shilpa Medicare, said Gate2Brain’s technology is one of the most promising platforms the company has evaluated for delivering drugs to the brain. He added that the investment allows Shilpa to participate in the long-term development of innovative cancer treatments while contributing its manufacturing expertise.
Meritxell Teixidó Turà, CEO of Gate2Brain, said the partnership with Shilpa provides the manufacturing strength and regulatory support needed to advance the program toward clinical development and eventual commercialization.
Company Overview
Shilpa Medicare is a leading Indian pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), formulations, biologics, and specialty medicines. The company has a strong presence in oncology, complex generics, drug delivery technologies, and contract development and manufacturing services, serving markets across more than 80 countries.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.inare their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Shilpa Medicare Subsidiary Acquires 30.4% Stake Worth ₹63 Cr in Spanish Biotech Firm Gate2Brain appeared first on Trade Brains.
Original Article
(Disclaimer – This post is auto-fetched from publicly available RSS feeds. Original source: Tradebrains. All rights belong to the respective publisher.)
